First Class Metals (FCM) the UK metals exploration company, reported that Palladium One continues to intersect potentially economic Ni-Cu mineralisation in and around the West Pickle Lake Joint Venture area. FCM said it remains encouraged with the progress the Palladium One exploration is making in the WPL zone and the wider discovery area. Particularly the success near to the FCM claim boundary with the results from TK23-128. FCM will continue to pursue third party interest in this sector of North Hemlo.
Comment: As today’s newsflow reminds us, since listing the progress of the company has been faultless in terms of proving up its assets, and indeed in this case other’s progress next door to FCM.
Wishbone Gold (WSBN) announced it has raised £300,000 gross to one corporate investor at a price of 1.2 pence. This small placing will provide additional working capital for the Company but importantly will primarily be used to initiate exploration operations at the new Mosquito Creek property in the Pilbara. WSBN said when raising fresh equity the board is mindful of dilution especially when share prices are depressed but has decided to do this micro-placing to secure the exploration funds needed for the recently acquired and very exciting Mosquito Creek gold and lithium project in Western Australia.
Comment: We have a new micro-placing concept from WSBN, something which underlines the sizzle that the Mosquito Creek gold asset could have in terms of bringing fresh interest to the company.
Hemogenyx Pharmaceuticals (HEMO) announced that a patent application entitled Method of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using Bi-Specific Antibodies has been allowed to be issued as a patent by the United States Patent and Trademark Office. HEMO said it was excited by the decision of the United States Patent and Trademark Office to allow this patent application. This is a significant addition to the patent protection for CDX which remains one of its key product candidates for the future. This also solidifies our Company’s position as a leader in the area of conditioning bone marrow transplants.
Comment: As has happened quite frequently in terms of positive HEMO news, shares of the company have already had a decent run ahead of the news. Nevertheless, the company is now undeniably a more serious contender in its space than even as recently as a couple of years ago.
Atlantic Lithium (ALL), the African-focussed lithium exploration and development company targeting to deliver Ghana’s first lithium mine, announced that the Company will be attending the Investing in African Mining Indaba Conference in Cape Town from Monday, 5 to Thursday, 8 February 2024.
Comment: The City herd are heading to Indaba, as something of a half term holiday of networking. Tough work, but all in a good cause.
SEEEN (SEEN), the global media and technology platform, announced that Adrian Hargrave, Chief Executive Officer, purchased a total of 60,000 ordinary shares on 1 February 2024 at a price of 5 pence per Ordinary Share via his ISA. Following the above share dealings, Adrian Hargrave has approximately 1.13% of the Company’s issued ordinary share capital.
Comment: Especially in current stock market conditions, CEOs leading from the front and buying their shares is significant. This is especially the case as far as SEEEN is concerned, in the wake of the latest positive trading update.
Psych Capital (AQSE:PSY), an investment firm focused on innovative drug-development in the field of mental health, reported that the phase 1 POC study of psilocybin-assisted therapy for anorexia nervosa patients conducted by the Department of Eating Disorders at the Sheba Medical Center has been awarded an additional grant from the newly founded IPR-TLV, the Institute for Integrative Psychedelic Research at the University of Tel-Aviv. PSY said despite the on-going war in Israel, and perhaps because of it, it sees a growing consideration of innovative treatments for mental health conditions, which are known to be exacerbated in war and crisis environments. It expects this to advance regulatory acceptance of psychedelic based medicine for mental health issues in Israel.
Comment: Given how important mental health has become in the Age of Woke, one would expect PSY shares to be rather higher in range given the progress the company is clearly making in the space.